(Q34202556)

31 July 2017

1 reference

title

Current and novel therapies for Lyme disease (English)

1 reference

31 July 2017

0 references

Charles S Pavia

1

1 reference

PubMed ID

12783604

31 July 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

1 reference

31 July 2017

12

1 reference

31 July 2017

6

1 reference

31 July 2017

1003-1016

1 reference

Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Lyme disease-a tick-borne spirochetosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Isolation of Borrelia burgdorferi from the blood of seven patients with Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

European Lyme borreliosis: 231 culture-confirmed cases involving patients with erythema migrans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Evaluation of two-test serodiagnostic method for early Lyme disease in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Long-term Outcomes of Persons With Lyme Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Failure of treatment with cephalexin for Lyme disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Failure to isolate Borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: report of a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Comparison of Cefuroxime Axetil and Doxycycline in the Treatment of Early Lyme Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Oxygen tensions and infections: modulation of microbial growth, activity of antimicrobial agents, and immunologic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Borrelia recurrentis infection: single-dose antibiotic regimens and management of the Jarisch-Herxheimer reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Management of syphilis in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

In vivo activity and pharmacokinetics of ziracin (SCH27899), a new long-acting everninomicin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

The Spirochetal Etiology of Lyme Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.6.1003

10.1517/13543784.12.6.1003

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

12783604